Accepted Manuscript NJC



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the **Ethical guidelines** still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/njc

**PAPER**

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

# **A Novel One pot four-component reaction for the efficient synthesis of spiro[indoline-3,4'-pyrano[2,3-***c***]pyrazole]-3'-carboxylate and trifluoromethylated spiro[indole-3,4'-pyrano[2,3-***c***]pyrazole] derivatives using recyclable PEG-400**

<sup>5</sup>**K. Karnakar, K. Ramesh, K. Harsha Vardhan Reddy, B. S. P. Anil Kumar, Jagadeesh Babu Nanubonula and Y. V. D. Nageswar\*** 

*Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX*  **DOI: 10.1039/b000000x** 

**A novel, simple and efficient synthetic protocol has been developed for the synthesis of spiro[indoline-3,4'-pyrano[2,3-**

10 *c***]pyrazole]-3'-carboxylate and trifluoromethylated spiro[indole-3,4'-pyrano[2,3-***c***]pyrazole] derivatives via a one pot, fourcomponent reaction using recyclable polyethylene glycol (PEG-400). This new protocol produces novel spiro pyranopyrazole derivatives in good to excellent yields, with operational simplicity and recycling of PEG-400. The remarkable features of this methodology are high yields, easy work-up process, and a greener method by avoiding toxic catalyst and hazardous solvents.**

#### **Introduction**

- 15 The design of multicomponent reactions (MCRs) is a significant field of research from the point of view of combinatorial chemistry.<sup>1</sup> Multi-component reactions, involving the intrinsic formation of several bonds in one step, have proven to be efficient and a powerful tool for the rapid formation of
- $_{20}$  complex heterocyclic compounds in recent years.<sup>2</sup> MCR strategy is an important approach utilized by researchers worldwide, to create several libraries of molecules of miscellaneous biological activities and has gained prominence in organic, medicinal and combinatorial chemistry.<sup>3</sup> In most of the cases, a single product
- <sup>25</sup>was obtained from three or more different substrates by reacting in a well-defined manner through MCRs.<sup>4</sup> These time-efficient reactions are environmentally benign and atom economic. MCRs are cost-effective since the expensive purification processes as well as protection-deprotection steps are non-existent.<sup>5</sup> Although
- 30 the first MCR dates back to the Strecker synthesis<sup>6</sup> of α-amino acid in 1850, the MCR strategy has been utilized successfully in Hantsch's synthesis of 1,4-dihydropyridines<sup>7</sup> and Robinson's synthesis of alkaloid tropinone.<sup>8</sup> Consequently, rapid development is observed in three- and four-component reactions.
- <sup>35</sup>Polyethylene glycol (PEG), a biologically acceptable polymer used widely in drug delivery and in bioconjugates as tool for diagnostics, has hitherto not been broadly used as a solvent

† Electronic Supplementary Information (ESI) available: [details of any <sup>45</sup>supplementary information available should be included here]. See DOI: 10.1039/b0000000x/

medium but has been used as a support for various 50 transformations.<sup>9</sup> Polyethylene glycol (PEG) and modified polyethylene glycol derivatives have been admired as efficient alternate reaction media, due to their remarkable features like non-toxicity, low cost, recoverability, bio-degradability and biocompatibility when compared to other **"**neoteric solvents" such as  $55$  ionic liquids, super-critical fluids and micellar systems.<sup>10</sup> PEG is most commonly employed as a phase-transfer catalyst in various organic transformations.<sup>11</sup> PEG is also used as a recyclable reaction medium in various substitution reactions,<sup>12</sup> oxidation and reduction reactions,<sup>13</sup> asymmetric dihydroxylation,<sup>14</sup> Heck 60 reaction,<sup>15</sup> Wacker reaction,<sup>16</sup> Suzuki cross-coupling reaction,<sup>17</sup> and partial reductions of alkynes.<sup>18</sup>



**Fig. 1** Some biologically active important molecules containing <sup>65</sup>Spirooxindole motif.

Potential biological activities and widespread synthetic utilities of spirocyclic compounds have led to their identification as a class of heterocyclic compounds, which has created considerable interest in the pharmaceutical industry and in the <sup>70</sup>diversified field of organic synthesis due to their steric strain associated with the quaternary carbon.<sup>19</sup> Moreover, increased

<sup>40</sup>MCP Division, Indian Institute of Chemical Technology,

Hyderabad 500607, India

Fax: +91-40-27160512 E-mail: dryvdnageswar@gmail.com

90

 $05$ 

potentiality is generally observed when two or more different heterocyclic moieties exist in a single molecule.<sup>20</sup> Isatin based spiro compounds or spirooxindoles are important core structures found in many natural alkaloids as well as synthetic *s* pharmaceuticals<sup>21</sup> such as spirotryprostatin (A & B), NTD609,

- Pteropodine and strychnofoline,<sup>22</sup> (Fig.1). Recent development of new protocols for the construction of spirocyclic compounds is an interesting and challenging task in organic synthesis. Moreover, dihydropyrano[2,3-c]pyrazole skeleton is an important core unit
- 10 to exhibit a wide range of biological activities such as antiinflammatory, antimicrobial, anticancer and molluscicidal activities.<sup>23</sup>

It is well known that the fluorine containing heterocyclic compounds often results in dramatic modification of their

- 15 physical, chemical and biological properties.<sup>24</sup> Especially, the trifluoromethyl group is a key structural unit in many fluorinated compounds of biological and pharmaceutical significance. As a result, trifluoromethyl substituted organic molecules exhibit interesting biological activities with potential for applications in
- $20$  the medicinal and agricultural fields.<sup>25</sup> Due to their significant and diverse biological activities design and widening the scope of novel methods for the construction of trifluoromethylated compounds are the challenging task for researchers involved in this particular field.
- <sup>25</sup> Herein, we sought to develop a single structural framework by combining spirooxindole, pyran, and pyrazole motifs for emergent interest in designing novel polycyclic heterocycles by combining various structurally diverse motifs. Recently, Choudhury *et al*., developed spiro[indoline-3,4'-
- <sup>30</sup>pyrano[2,3-*c*]pyrazole]-3'-carboxylate derivatives in the presence of triethylamine and ethanol.<sup>26</sup> Song *et al*., synthesized trifluoromethylated spiro pyranopyrazole derivatives from isatin, malononitrile, hydrazine hydrate and ethyl 4,4,4 trifluoroacetoacetate as a starting materials.<sup>27</sup> Very recently, Pore
- <sup>35</sup>*et al*., reported novel spiro pyranopyrazole derivatives from isatin, malononitrile, hydrazine hydrate and dialkyl acetylenedicarboxylates in the presence of ethanol and water mixture.<sup>28</sup>
- Despite the importance of these reported protocols, <sup>40</sup>many suffer from drawbacks such as use of expensive reagents, prolonged reaction times, harsh reaction conditions, cumbersome product isolation procedures, and low yields. Sustainable chemistry has gained prominence recently due to its environmental compatibility. To explore a mild, efficient and <sup>45</sup>environmentally benign recyclable synthetic protocol, we have
- demonstrated the synthesis of Pyrazolo[3,4-b]quinoline derivatives in the presence of  $PEG-400<sup>29</sup>$  In our continued quest for the development of eco-friendly protocols $30$  and considering the significant biological activities of spirooxindoles, herein, we
- <sup>50</sup>report a one-pot four-component reaction for the synthesis of novel spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3'-carboxylate derivatives using recyclable PEG-400 as a reaction medium (**Scheme 1**).



**Scheme 1** Synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3' carboxylate derivatives using PEG-400

#### **Results and Discussion**

Initially, a model reaction was conducted by taking isatin (1.0 mmol), malononitrile (1.0 mmol), dimethyl acetylenedicarboxylate (DMAD) (1.0 mmol) and hydrazine hydrate (1.0 mmol) at 40-50  $^{\circ}$ C and the desired product was obtained in 30% yield, along with the unreacted starting <sup>65</sup>materials, even after prolonged reaction time (24 h). To explore the ideal reaction conditions to get maximum product yield several reactions were conducted. During this optimization study, it was observed that  $100-110$  <sup>0</sup>C is ideal temperature for the reaction. After optimizing the experimental conditions, 5-  $70$  methoxy isatin (1.0 mmol), malononitrile (1.0 mmol) dimethy acetylene dicarboxylate(DMAD) (1.0 mmol) and hydrazine hydrate (1.0 mmol) were reacted in the presence of recyclable polyethylene glycol (PEG)-400, resulting in the formation of the desired spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3'-carboxylate <sup>75</sup>derivative in excellent yield (Table 1, Entry 1). To expand the scope of this protocol, different experiments were conducted with various substituted isatins and these results were tabulated in Table 1. It was observed that this protocol was also effective with N-substituted isatins such as N-CH<sup>3</sup> , N-Ph, N-Benzyl isatins <sup>80</sup>resulting in good yields. Apart from malononitrile, reactions with methyl cyanoacetate and ethyl cyanoacetates were also conducted resulting in corresponding spiro[indoline-3,4'-pyrano[2,3 *c*]pyrazole]-3'-carboxylate derivatives in moderate yield. Scope of the protocol was also extended with diethyl 85 acetylenedicarboxylate under similar reaction conditions and the results are summarized in Table 1. This protocol was also extended a step further, using phenyl hydrazine in place of hydrazine component, providing the desired spiro[indoline-3,4' pyrano[2,3-*c*]pyrazole]-3'-carboxylate derivatives in good yield.



**Scheme 2** Synthesis of trifluoromethylated spiro[indoline-3,4' pyrano[2,3-*c*]pyrazole] derivatives using PEG-400

We further synthesized a variety of trifluoromethylated spiro[indole-3,4'-pyrano[2,3-*c*]pyrazole] derivatives (**Scheme 2**) using ethyl 4,4,4-trifluoroacetoacetate in place of dialkyl acetylenedicarboxylate affording products in good yields. In <sup>5</sup>continuation of further explorations of this method, several reactions were also conducted with various substituted isatins and these results were tabulated in Table 2. All these products were

characterized by spectroscopic and analytical methods.

<sup>10</sup>**Table 1:** Synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3' carboxylate derivatives using PEG-400<sup>a</sup>.







a Reaction conditions: Isatin (1.0 mmol), Malononitrile (1.0 mmol), Dialkyl acetylene dicarboxylate (1.0 mmol), Hydrazine hydrate (1.0  $20 \text{ mmol}$ ) and PEG-400 at 110-110  $^0$ C.  $^b$  Isolated yields.

**Table 2:** Synthesis of trifluoromethylated spiro[indoline-3,4'-pyrano[2,3  $c$ ]pyrazole] derivatives using PEG-400 $^{\circ}$ .



<sup>a</sup> Reaction conditions: Isatin (1.0 mmol), Malononitrile (1.0 mmol), Ethyl 4,4,4-trifluoroacetoacetate (1.0 mmol), Hydrazine hydrate (1.0 mmol) and PEG-400 at  $110-110$  °C. <sup>b</sup> Isolated yields.

15

A plausible mechanism was proposed for the general synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3' carboxylates using this present protocol in scheme 3. Initially, Knoevenagel condensation occurs between isatin and 5 malononitrile, forming the adduct (A), which reacts with the pyrazolone intermediate (B) formed by the condensation of dialkyl acetylene dicarboxylate and hydrazine hydrate. This crucial step involves Michael addition of B onto intermediate (A), followed by enolization and ring closure providing the desired 10 product (C) as reported in the literature and it was further

supported by X-ray crystallography <sup>31</sup> (**Figure 2**).



**Figure 2.** ORTEP diagram of compound Table 1 Entry 3 with the atom-<sup>15</sup>numbering scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii. The solvent of crystallization acetone was also included in the crystal lattice. The asymmetric unit containing 1:1 stoichiometric ratio of compound and acetone is shown. Only major component of the <sup>20</sup>disordered atoms is shown for clarity.



<sup>25</sup>**Scheme 3:** Plausible mechanism

#### **Conclusions**

In conclusion, we have developed a simple and highly efficient greener approach for the one-pot, four-component <sup>30</sup>synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3' carboxylate and trifluoromethylated spiro[indole-3,4'-pyrano[2,3 *c*]pyrazole] derivatives by using PEG-400 as inexpensive, biodegradable, and reusable reaction medium. This novel protocol generates five new bonds in one sequence. The salient 35 features of this methodology are efficiency, environmentally benign nature and high yield, wider scope of substrate choice, ease of product purification, non-involvement of hazardous catalysts or toxic solvents.

### **Experimental Section**

#### <sup>40</sup>**General procedure for the synthesis of spiro[indoline-3,4' pyrano[2,3-***c***]pyrazole]-3'-carboxylate / trifluoromethylated spiro[indole-3,4'-pyrano[2,3-***c***]pyrazole] derivatives:**

To a stirred solution of polyethylene glycol (PEG)-400 (5 mL), isatin (1.0 mmol), and malononitrile (1.0 mmol) were 45 added and stirred at 100 - 110 °C for 20 min. Then a solution of hydrazine hydrate (1.0 mmol) and dialkyl acetylenedicrboxylate / ethyl 4,4,4-trifluoroacetoacetate (1.0 mmol) in PEG-400 was added to it. The whole reaction mixture was stirred until the reaction was complete as indicated by TLC. After completion of <sup>50</sup>the reaction, ether (5mL) was added and stirred for a 5-10 mins and cooled to -50 $\degree$ C. At this temperature PEG became solid and the ether layer saturated with product was separated and

evaporated. The crude product was purified by column chromatography, using hexane and EtOAc as eluent to provide <sup>55</sup>the title compound. The recovered PEG was reused for further cycles. For the NMR spectroscopic analysis the title compound was dissolved in the ratio of solvents Acetone- $d_6$  and DMSO- $d_6$  is

#### 4:1. **Characterization of selected compounds:**

60 *Methyl 6'-amino-5'-cyano-5-methoxy-2-oxo-2'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-3'-carboxylate (Table 1, Entry 1):* IR (KBr) 3445, 3275, 3185, 2933, 2192, 1710, 1635, 1494, 1222, 1089 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, Acetone-

d<sub>6</sub>+DMSO-d<sub>6</sub>)  $\delta$  9.83 (s, 1H), 6.89 (d,  $J = 8.4$  Hz, 1H), 6.80-6.76 (m, 1H), 6.74 – 6.70 (m, 1H), 6.67 (s, 2H), 3.69 (s, 3H), 3.52 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, Acetone-d<sub>6</sub>+DMSO-d<sub>6</sub>)  $\delta$  177.3, 161.3, 158.0, 155.9, 135.8, 135.3, 129.2, 128.7, 117.5, 113.4, <sup>5</sup>110.6, 109.7, 101.1, 58.7, 55.0, 51.0, 48.3 ppm. ESI-MS: 368

 $(M+H)$ <sup>+;</sup>  $C_{17}H_{14}N_5O_5$ .

*Methyl 6'-amino-5-chloro-5'-cyano-2-oxo-2'H-spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-3'-carboxylate (Table 1, Entry 2):* IR (KBr) 3442, 3275, 3180, 2933, 2185, 1710, 1622, 1494, 1222,

 $10^{10}$  1089 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, Acetone-d<sub>6</sub>+DMSO-d<sub>6</sub>) δ 10.60  $(s, 1H)$ , 7.26-7.23 (m, 1H), 7.10-7.14 (m, 3H), 6.97 (d,  $J = 8.3$ ) Hz, 1H), 3.55 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, Acetoned<sub>6</sub>+DMSO-d<sub>6</sub>) δ 177.2, 161.2, 157.9, 156.3, 141.5, 136.1, 128.9, 128.4, 126.3, 124.1, 117.6, 110.7, 100.3, 57.1, 51.2, 48.0 ppm. 15 ESI-MS: 372 (M+H)<sup>+;</sup>  $C_{16}H_{11}CIN_5O_4$ .

*Methyl 6'-amino-5-bromo-5'-cyano-2-oxo-1'-phenyl-1'Hspiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-3'-carboxylate (Table 1, Entry 3):* IR (KBr) 3444, 3273, 3180, 2930, 2182, 1715, 1622, 1494, 1220, 1085 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, Acetone-d<sub>6</sub>+DMSO-

d6 <sup>20</sup>) δ 10.34 (s, 1H), 7.89 (d, *J* = 8.1 Hz, 2H), 7.64 (t, *J* = 8.1 Hz, 1H), 7.34 (t, *J* = 7.5 Hz, 1H), 7.19-7.16 (m, 3H), 7.10 (d, *J* = 7.1 Hz, 1H), 6.98-6.92 (m, 2H), 3.48 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, Acetone- $d_6$ +DMSO- $d_6$ )  $\delta$  177.8, 160.6, 159.0, 142.4, 138.3, 137.5, 134.0, 129.5, 128.7, 128.1, 125.4, 124.0, 122.4,

<sup>25</sup>122.0, 121.8, 117.2, 109.5, 59.2, 51.0, 48.5 ppm. ESI-MS: 492  $(M+H)$ <sup>+;</sup> C<sub>22</sub>H<sub>15</sub>BrN<sub>5</sub>O<sub>4</sub>. *Methyl 6'-amino-5'-cyano-5-methoxy-2-oxo-1'-phenyl-1'H-*

*spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-3'-carboxylate (Table 1, Entry 5):* IR (KBr) 3440, 3278, 3180, 2933, 2185, 1710, 1622,

- $_{30}$  1494, 1222, 1089 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, Acetone-d<sub>6</sub>+DMSOd6 ) δ 9.93 (s, 1H), 7.43 (m, 3H), 7.28 (m, 2H), 6.91 (d, *J* = 8.4 Hz, 1H), 6.82-6.79 (m, 1H), 6.74 – 6.70 (m, 1H), 6.64 (s, 2H), 3.71 (s, 3H), 3.52 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, Acetone $d_6$ +DMSO- $d_6$ ) δ 177.2, 160.4, 159.9, 155.5, 146.3, 138.0, 137.0,
- <sup>35</sup>135.8, 135.0, 129.3, 127.9, 121.6, 117.1, 113.2, 110.7, 109.6, 99.1, 59.0, 55.0, 50.6, 48.6 ppm. ESI-MS: 444  $(M+H)$ <sup>+</sup>;  $C_{23}H_{18}N_5O_5.$

 *6'-Amino-5-methoxy-2-oxo-3'-(trifluoromethyl)-2'H-*

- *spiro[indoline-3,4'-pyrano[2,3-c]pyrazole]-5'-carbonitrile (Table*  <sup>40</sup>*2, Entry 1):* IR (KBr) 3470, 3311, 3175, 3105, 2205, 1711, 1648, 1501, 1402, 1336, 1146, 1018 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, acetone $d_6$ ) δ= 9.51 (s, 1H), 6.94-6.83 (m, 3H), 6.66 (s, 2H), 3.72 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, acetone-d<sub>6</sub>):  $\delta$  49.6, 56.9, 60.6, 112.1, 113.2, 116.3, 118.6, 123.2, 130.5, 135.6, 136.7, 136.8, 158.1,
- 45 163.0, 178.7 ppm. ESI-MS: 378 (M+H)<sup>+</sup>; C<sub>16</sub>H<sub>11</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>.

### **Acknowledgments**

We thank CSIR, New Delhi, India, for fellowships to K.K, K.H.V.R, B.S.P, K. D. and UGC for fellowship to K.R.

### <sup>50</sup>**References**

- 1. (a) L. Weber, K. Illegen and M. Almstetter, *Synlett* 1999, 366; (b) R. W. Armstrong, A. P. Combs, P. A. Tempest, S. D. Brown and T. A. Keating, *Acc*. *Chem*. *Res*. 1996, **29**, 123.
- 2. (a) B. Jiang, T. Rajale, W. Wever, S.-J. Tu and G. Li, *Chem.: Asian*  <sup>55</sup>*J.* 2010. doi:10.1002/asia.201000310; (b) S. Maiti, S. Biswas and U. Jana, *J. Org. Chem.* 2010, **75**, 1674; (c) L. F. Tietze, G. Brasche and K. M. Gericke, Domino Reactions in Organic Synthesis; *Wiley-VCH:*

*Weinhein*, 2006; (d) A.; de Meijere, P. von Zezschwitz and S. Brase, *Acc. Chem. Res.* 2005, **38**, 413. and references cited therein.

- <sup>60</sup>3. (a) H. Bienayme, C. Hulme, G.; Oddon and P. Schmitt, *Chem. Eur. J*. 2000, **6**, 3321-3329; (b) G. Balme, E. Bossharth and N. Monteiro, *Eur. J. Org. Chem.* 2003, **21**, 4101-4111; (c) S. Brase, C. Gil and K. Knepper, *Bioorg. Med. Chem.* 2002, **10**, 2415-2437; (d) A. Domling and I. Ugi, *Angew. Chem. Int. Ed.* 2000, **39**, 3168-3210.
- <sup>65</sup>4. (a) P. A. Tempest, *Curr. Opin. Drug Disco*v*ery* 2005, **8**, 776; (b) H. Fujioka, K. Murai, O. Kubo, Y. Ohba and Y. Kita, *Org. Lett.* 2007, **9**, 1687; (c) N. M. Evdokimov, A. S. Kireev, A. A. Yakovenko, M. Y. Antipin, I. V. Magedov and A. Kornienko, *J. Org. Chem.* 2007, **72,** 3443; (d) X. S. Wang, Q. Li, J. R. Wu, Y. L. Li, C. S. Yao, S. J. Tu, <sup>70</sup>*Synthesis* 2008, 1902.
- 5. (a) B. M. Trost, *Angew. Chem. Int. Ed.* 1995, **34**, 259; (b) P. A. Wender, S. T. Handy and D. L. Wright, *Chem. Ind.* 1997, 765.
- 6. A. Strecker, *Liebigs Ann*. *Chem*. 1850, **75**, 27.
- 7. A. Hantzsch, *Justus Liebigs Ann*. *Chem*. 1882, **215**, 1.
- <sup>75</sup>8. R. Robinson, *J*. *Chem*. *Soc*. *(London*) 1917, **111**, 876. 9. (a) V. N. Vasudevan and S. V. Rajender, *Green Chem.* 2001, **3**, 146– 148; (b) A. Haimov, R. Neumann, *Chem. Commun.* 2002, 876–877; (c) L. Heiss and H. J. Gais, *Tetrahedron Lett.* 1995, **36**, 3833–3836; (d) T. J. Dickerson, N. N. Reed and K. D. Janda, *Chem. Rev.* 2002, <sup>80</sup>**102**, 3325–3344.
	- 10. J. Chen, S. K. Spear, J. G. Huddleston and R. D. Rogers, *Green. Chem*., 2005, **7,** 64
	- 11. K. Z. Andrade and L. M. Alves, *Curr. Org. Chem.* 2005, **9**, 195.
- 12. P. Ferravoschi, A. Fiecchi, P. Grisenti, E. Santaniello and S. Trave,
- <sup>85</sup>*Synth. Commun.,* 1987, **17**, 1569.
- 13. J. R. Blanton, *Synth. Commun.,* 1997, **27**, 2093.
- 14. S. Chandrasekhar, Ch. Narsihmulu, S. S. Sultana and N. R. K. Reddy, *Chem. Commun.,* 2003, 1716.
- 15. S. Chandrasekhar, Ch. Narsihmulu, S. S. Sultana, and N. R. K. <sup>90</sup>Reddy, *Org. Lett.,* 2002, **4**, 4399.
- 16. A. Haimov and R. Neumann, *Chem. Commun.*, 2002, 876.
- 17. V. V. Namboodiri and R. S. Varama, *Green. Chem*., 2001, **3**, 146.
- 18. S. Chandrasekhar, Ch. Narsihmulu, G. Chandrasekhar and T. Shyamsundar, *Tetrahedron Lett.* 2004, **45**, 2421.
- <sup>95</sup>19. S. T. Hilton, T. C. T. Ho, G. Pljevalijcic and K. Jones, *Org. Lett.* 2000, **17**, 2639.
- 20. R. Balini, G. Bosica, M. Conforti, R. Magi, A. Mazzacannt, P. Righi and G. Sarton, *Tetrahedron* 2001, **57**, 1395.
- 21. (a) T. H. Kang, K. Matsumoto, Y. Murakami, H. Takayama, M. <sup>100</sup>Kitajima, N. Aimi and H. Watanabe, *Eur. J. Pharmacol.* 2002, **444**, 39; (b) S. Edmondson, S. Danishefsky, L. Sepp-lorenzinol and N. Rosen, *J. Am. Chem. Soc.* 1999, **121**, 2147.
- 22. (a) C. B. Cui, H. Kakeya and H. Osada, *Tetrahedron* 1996, **52**, 12651–12666; (b) C. B. Cui, H. Kakeya and H. Osada, *J. Antibiot.* 105 1996, **49**, 832–835; (c) M. Rottmann, C. McNamara, B. K. S. Yeung, M. C. S. Lee, B. Zou, B. Russell, P. Seitz, D. M. Plouffe, N. V. Dharia, J. Tan, S. B. Cohen, K. R. Spencer, G. E. González-Páez, S. B. Lakshminarayana, A. Goh, R. Suwanarusk, T. Jegla, E. K.
- Schmitt, H.-P. Beck, R. Brun, F. Nosten, L. Renia, V. Dartois, T. H. <sup>110</sup>Keller, D. A. Fidock, E. A. Winzeler and T. T. Diagana, *Science* 2010, **329**, 1175–1180; (d) C. V. Galliford and K. A. Scheidt, *Angew. Chem., Int. Ed.* 2007, **46**, 8748–8758.
- 23. (a) M. E. A. Zaki, H. A. Soliman, O. A. Hiekal and A. E. Z. Rashad, *Naturforsch.* 2006, **61**, 1–5; (b) E. H. El- Tamany, F. A. El-Shahed
- <sup>115</sup>and B. H. Mohamed, *J. Serb. Chem. Soc.* 1999, **64**, 9–18; (c) J. L. Wang, D. Liu, Z. J. Zhang, S. Shan, X. Han, S. M. Srinivasula, C. M. Croce, E. S. Alnemri and Z. Huang, *Proc. Natl. Acad. Sci.* U.S.A. 2000, **97**, 7124–7129; (d) F. M. Abdelrazek, P. Metz, N. H. Metwally and S. F. El-Mahrouky, *Arch. Pharm.* 2006, **339**, 456–460; (e) F. M. <sup>120</sup>Abdelrazek, P. Metz, O. Kataeva, A. Jaeger and S. F. El-Mahrouky, *Arch. Pharm.* 2007, **340**, 543–548.
- 24. R. E. Bank, *Organofluorine Chemistry: Principles and Commercial Application*, Plenum and Elsevier, New York, 1994. R. E. Filler, *Organic Chemistry in Medicinal Chemistry and Biochemical*  <sup>125</sup>*Applications*, Plenum and Elsevier, Amsterdam, 1993. (a) B. E. Smart, *J. Fluorine Chem*., 2001, **109**, 3–11; (b) N. Iwai, R. Sakai, S. Tsuchida, M. Kitazume and T. Kitazume, *J. Fluorine Chem*., 2009, **130**, 434–437; (c) W. R. Dolbier Jr., *J. Fluorine Chem*., 2005, **126**, 157–163;
- 25. (a) J. T. Welch, *Tetrahedron* 1987, **43**, 3123–3197; (b) M. Frezza, D. Balestrino, L. Soule' re, S. Reverchon, Y. Queneau, C. Forestier and A. Doutheau, *Eur. J. Org. Chem.* 2006, 4731–4736; (c) F. Leroux, O. Lefebvre and M. Schlosser, *Eur. J. Org. Chem.* 2006, 3147–3151;
- <sup>5</sup>26. S. Pal, Md. N. Khan, S. Karamthulla, S. J. Abbas and L. H. Choudhury; *Tetrahedron Lett*. 2013, **54**, 5434.
- 27. Xiaoqing Liu, Xiaoling Xu, Xu Wang, Wenxin Yang, Qun Qian, Min Zhang, Liping Song, Hongmei Deng and Min Shao; *Tetrahedron Lett*. 2013, **54**, 4451.
- <sup>10</sup>28. D. M. Pore, P. B. Patil, D. S. Gaikwad, P. G. Hegade, J. D. Patil and K. A. Undale; *Tetrahedron Lett*. 2013, **54**, 5876.
- 29. K. Karnakar, S. N. Murthy, K. Ramesh, G. Satish. N. Jagadeesh Babu and Y. V. D. Nageswar, *Tetrahedron Lett*. 2012, **53**, 2897.
- 30. (a) K. Karnakar, A. V. Kumar, S. N. Murthy, K. Ramesh and Y. V. <sup>15</sup>D. Nageswar, *Tetrahedron Lett*. 2012, **53**, 4613; (b) K. Karnakar, S. N. Murthy, K. Ramesh, K. H. V. Reddy, Y. V. D. Nageswar, U. Chandrakala, B. L. A. Prabhavathi Devi and R. B. N. Prasad, *Tetrahedron Lett*. 2012, **53**, 3497; (c) K. Karnakar, S. N. Murthy, K. Ramesh, Y. V. D. Nageswar, T. V. K. Reddy, B. L. A. Prabhavathi
- <sup>20</sup>Devi and R. B. N. Prasad, *Tetrahedron Lett*. 2012, **53**, 1968; (d) J. Shankar, K. Karnakar, B. Srinivas and Y. V. D. Nageswar, *Tetrahedron Lett.* 2010, **51**, 3938; (e) K. Karnakar, J. Shankar, S. N. Murthy, K. Ramesh and Y. V. D. Nageswar, *Synlett* 2010, **51**, 5252; (f) K. Ramesh, K. Karnakar, G. Satish, K. H. V. Reddy and Y. V. D.
- <sup>25</sup>Nageswar, *Tetrahedron Lett.* 2012, **53**, 6095; (g) B. S. P. Anil Kumar, B. Madhav, K. H. V. Reddy and Y. V. D. Nageswar. *Tetrahedron Lett.* 2011, **52**, 2862.
- 31. **Crystal data for Table 1 Entry 3**: The compound was crystallized from acetone solvent using the slow evaporation method. The acetone <sup>30</sup>was included in the crystal lattice. The asymmetric unit contains the

compound and acetone in 1:1 ratio. Molecular formula,  $C_{22}H_{14}BrN_5O_4 \cdot C_3H_6O$ ,  $M = 550.37$ , colourless block, 0.42 x 0.38 x

0.29 mm<sup>3</sup>, triclinic, space group  $P_1^1$  (No. 2), a = 10.107(3), b = 11.058(3),  $c = 12.667(3)$ Å,  $\alpha = 71.325(4)$ ,  $\beta = 71.161(4)$ ,  $\gamma =$ 

- 35 78.620(4)°,  $V = 1262.4(6)$  Å<sup>3</sup>,  $Z = 2$ ,  $Dc = 1.448$  g/cm<sup>3</sup>,  $F_{000} = 560$ , CCD area detector, MoK $\alpha$  radiation,  $\lambda = 0.71073$  Å,  $T = 293(2)$ K,  $2\theta_{\text{max}} = 56.56^{\circ}$ , 14880 reflections collected, 5935 unique ( $R_{\text{int}} =$ 0.022), Final GooF = 1.038,  $R1 = 0.0468$ ,  $wR2 = 0.1409$ , *R* indices based on 4013 reflections with  $I > 2\sigma(I)$  (refinement on  $F^2$ ), 378
- 40 parameters, 34 restraints,  $\mu = 1.673$  mm<sup>-1</sup>, minimum and maximum residual density,  $-0.24$  and  $0.67$  e/ $\AA$ <sup>3</sup>. CCDC 982356 contains supplementary crystallographic data for the structure. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge
- <sup>45</sup>Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk. The full details of crystal data collection and refinement was provided in supporting information.

# **Graphical Abstract**

# **A Novel One pot four-component reaction for the efficient synthesis of spiro[indoline-3,4'-pyrano[2,3-***c***]pyrazole]-3'-carboxylate and trifluoromethylated spiro[indole-3,4'-pyrano[2,3-***c***]pyrazole] derivatives using recyclable PEG-400.**

## **K. Karnakar, K. Ramesh, K. Harsha Vardhan Reddy, B. S. P. Anil Kumar, Jagadeesh Babu Nanubonula and Y. V. D. Nageswar\***

A novel, simple and efficient synthetic protocol has been developed for the synthesis of spiro[indoline-3,4'-pyrano[2,3-*c*]pyrazole]-3'-carboxylate and trifluoromethylated spiro[indole-3,4'-pyrano[2,3-*c*]pyrazole] derivatives via a one pot, four-component reaction using recyclable PEG-400.

